Short Interest in Evoke Pharma, Inc. (NASDAQ:EVOK) Decreases By 83.2%

Evoke Pharma, Inc. (NASDAQ:EVOK) was the target of a significant decrease in short interest in November. As of November 15th, there was short interest totalling 17,000 shares, a decrease of 83.2% from the October 31st total of 101,000 shares. Based on an average trading volume of 379,700 shares, the days-to-cover ratio is currently 0.0 days. Currently, 1.3% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on Evoke Pharma in a research note on Wednesday, November 20th. They issued a “sell” rating for the company.

Hedge Funds Weigh In On Evoke Pharma

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. acquired a new stake in Evoke Pharma, Inc. (NASDAQ:EVOK) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned approximately 1.42% of Evoke Pharma at the end of the most recent quarter.

Evoke Pharma Stock Performance

Evoke Pharma stock traded down $0.02 during mid-day trading on Wednesday, reaching $4.37. The stock had a trading volume of 13,630 shares, compared to its average volume of 125,219. The firm has a market capitalization of $6.51 million, a PE ratio of -0.40 and a beta of 0.36. Evoke Pharma has a fifty-two week low of $3.54 and a fifty-two week high of $17.40. The stock’s 50-day simple moving average is $5.15 and its 200-day simple moving average is $5.43.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.